Please login to the form below
Merck KGaA
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.
Merck KGaA gains exclusive rights to Debiopharma’s late-stage oncology asset
Merck KGaA will pay Debiopharm 188m upfront and up to 710m in regulatory and commercial milestones, as well as royalty payments, for the exclusive rights to xevinapant. ... high unmet need where other approaches, including immunotherapy, have seen
Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance
Bispecific antibody fails in non-small cell lung cancer trial. Bintrafusp alfa – the novel immunotherapy at the centre of a major alliance between GlaxoSmithKline (GSK) and Merck KGaA – has failed in ... program,” said Danny Bar-Zohar, global head
Merck KGaA signs deal with Artios Pharma potentially worth up to $860m
Under the terms of the agreement, Merck KGaA will pay Artios $30m upfront, as well as near-term payments. ... Artios could also receive royalty payments up to double digits on net sales of each product commercialised by Merck KGaA.
Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer
Drug approved in combination with Merck's KGaA's Erbitux. French pharma group Pierre Fabre’s Braftovi has been recommended for NHS use by the UK’s National Institute for Health ... Braftovi (encorafenib) combined with has been recommended Merck
Switzerland: a life sciences hub
When Merck acquired Serono, the company also acquired several manufacturing facilities in the canton of Vaud. ... The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline,
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Salary TBC
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Planner
-
Salary TBC
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
-
Publications Director
-
Competitive Salary
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
- FDA advisory committee overwhelmingly votes no on Biogen's aducanumab
- Israel finds a ‘probable link’ between Pfizer vaccine and myocarditis cases
- Servier, Oncodesign select first preclinical candidate from Parkinson’s disease collaboration
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Regeneron’s COVID-19 drug boosts survival in hospitalised patients lacking antibodies
- GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug
- Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3
- Your clinical trial participants are precious, so treat them as such
- Diversity and inclusion in clinical trials
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- Nicky Hutchens appointed as deputy managing director at Four Health
- Rediscovering the human touch in healthcare
- Lucid Group acquires US-based strategic brand consultants DiD
- FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
- Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....
- The power of communication: Engaging diverse groups in healthcare
- Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society - especially...
- Building the hospital of the future
- Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
